Description
brukinsa price
Brukinsa is a targeted cancer treatment used to treat certain blood cancers in adults, such as mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL). It is an oral capsule or tablet that is taken once or twice a day. brukinsa price
Brukinsa (zanubrutinib) works by blocking an enzyme called Bruton’s tyrosine kinase (BTK). This slows the growth and spread of malignant B cells, the abnormal white blood cells responsible for certain blood cancers. brukinsa price
Brukinsa first received FDA approval on November 14, 2019. Unlike older BTK inhibitors, Brukinsa was specifically designed for greater BTK selectivity and increased potency, which means it targets the BTK enzyme more precisely and is associated with fewer off-target effects. There is no generic version available.
Side effects
Common Side Effects
The most common side effects of Brukinsa are:
- decreased white blood cell count
- decreased platelet count
- cold-like symptoms (upper respiratory tract
infection) - muscle, bone, or joint pain.
Reviews
There are no reviews yet.